Since 1997 the European Randomised Study of Screening for Prostate Cancer (ERSPC) set the PSA > 3 ng/mL as an indication to prostate biopsy overlooking other imaging or clinical aspects6,24–29. The gene discussed is KLK3; the disease is prostate carcinoma.